ID
25940
Description
Study ID: 101468/169 Clinical Study ID: 101468/169 Study Title:A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00381472 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Parkinson Disease This is the L-Dopa Medication form.
Keywords
Versions (2)
- 9/17/17 9/17/17 -
- 9/28/17 9/28/17 -
Uploaded on
September 28, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
Similar models
GSK Ropinirole in Patients Suffering from Parkinsons Disease L-Dopa Medication 101468/169 NCT00381472
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,2])
C0869039 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0808070 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0023570 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,2])